Page 15 - Pharma Sector

Indian drugmakers to stay competitive despite US tariff plans: Dr Reddy's

The industry is still waiting for more clarity on any tariffs before taking any action, Prasad said on the sidelines of the BioAsia conference in the Southern Indian state of Telangana

Biocon share price up 2% as arm launches Yesintek in US; check details here

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available to patients in US

Pharma sector can deliver 100 new drugs by 2047: Zydus chairman

Indian pharma industry is capable of delivering 100 new drugs by 2047 for global markets backed by enhanced research and development efforts, Zydus Lifesciences Chairman Pankaj R Patel said on Friday. Speaking at an event here, he stressed the need for innovation, capability building, and a focus on societal benefit. "I believe India can deliver 100 new chemical entities or new drugs to the world by 2047 and off course, it will require effort," Patel said while speaking at the SOUL leadership conclave 2025. He termed it a myth that drug discovery requires a billion dollars while emphasising that it is possible with the right approach. Patel also asserted that the people working in an organisation are the most valuable resource and pitched for an environment where people love to work. He also emphasised the evolving nature of leadership, highlighting the importance of humility, vision, and a global perspective. Patel also shared experiences, including the Prime Minister's proactiv

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

NPPA directs pharma firms to update MRP after Budget 2025 duty exemptions

The National Pharmaceutical Pricing Authority directs pharma firms to revise the MRP of medicines following customs duty exemptions in Union Budget 2025, ensuring consumers benefit from lower prices

Aurobindo Pharma to begin supplies to Europe from China plant in April

Aurobindo Pharma will commence supplies to Europe from its China facility from April onwards, according to Chief Financial Officer Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up the production. "The China plant will start billing sometime in the month of April, mainly to the European markets," Subramanian told analysts in a call. The company has received European regulatory approvals and can initiate product supply to the market, he added. "We are in the process of getting it (in China) and after that there may be an inspection for the US (market) also," Subramanian said. The company expects good traction coming out of the China plant over the next 2-3 years, he noted. When asked about revenue projections, Subramanian stated: "This being the first year, we may not like to, but certainly I see a significant revenue coming up in two to three years' time." On a query regarding the ..

Nifty Pharma index slips 3%; Natco, Glenmark, Lupin, Laurus down up to 10%

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

PI Industries hits 52-week low; down 11% in one week on poor Q3 earnings

PI Industries' steady Q3FY25 performance, cautious near-term outlook, and portfolio challenges are likely to affect the business dynamics in FY26 and FY27, according to analysts.

Analysts bullish on Lupin after Q3; share pops 6%; Goldman Sachs ups target

Domestic, as well as global brokerages are optimistic about Lupin's future, citing strong earnings visibility and a promising product pipeline

Chemists' association seeks meeting with NPPA over price display issue

The NPPA, in an office memorandum (OM) dated February 4, had directed medicine retailers as well as online pharmacies to "conspicuously" display current drug price list

Medicine retailers, e-pharmacies asked to display DPCO's drug price list

National pharma pricing regulator says list has to be put up 'conspicuously'

Steel, pharma, chemicals: Top Indian sectors at risk of higher US tariffs

Countries that have free trade agreements with the US, such as Singapore and South Korea, are safer with respect to Trump's reciprocal tariff threat, analysts at Nomura said.

AstraZeneca's cancer drug tops list of new brands launched in 2024

Five of top 20 drug introductions target cancer, reflecting its rising incidence in India

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Pharma exports to touch $65 bn mark by 2030, $350 bn by 2047: Report

India's pharma exports are expected to double to USD 65 billion by 2030 and touch USD 350 billion in value terms by 2047, moving to top five position globally by diversifying its product basket, according to a report. While India is the largest supplier of generic drugs globally, accounting for one in five generic drugs sold worldwide, the nation ranks 11th in terms of export value. As per the Bain & Company's report, 'Healing the World: Roadmap for Making India a Global Pharma Exports Hub', India can potentially secure a position among the top five nations in export value by 2047 by innovating and diversifying its export basket to include specialty generics, biosimilars, and innovative products. The findings in the report were formulated in collaboration with Indian Pharmaceutical Alliance (IPA), Indian Drugs Manufacturers' Association (IDMA), and Pharmexcil. "The transition from volume-based to value-led growth is essential for Indian pharma to secure its rightful place in the ..

Indian pharma market registers over 8% growth in January 2025: Pharmarack

Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, and 6.9 per cent, respectively, driving overall IPM growth

Lilly forecasts 2025 profit above estimates on weight-loss drug strength

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter

Zydus Life up 3% on mixed Q3, mcap tops Rs 1 trn; analysts split on outlook

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which led to a PAT beat, analysts said

ICMR initiates process of vaccine development against avian influenza

The ICMR has initiated the process of development of an ingenious human vaccine candidate against highly-pathogenic avian influenza (H5N1). The Indian Council of Medical Research (ICMR) has invited expression of interest from the eligible organisations, companies, manufacturers for joint collaboration in research and development for development of human vaccine candidate against H5N1. The avian influenza H5N1, a highly pathogenic strain of bird flu, continues to pose a significant threat to animal and human health in India. Recent outbreaks in 2021, 2023 and 2024 have been reported in several states, primarily affecting poultry and wild birds, the expression of interest document said. These outbreaks have caused significant economic losses in the poultry industry and raised public health concerns due to the virus's zoonotic potential, it said. The document stated that avian influenza H5N1 virus poses a grave public health risk because of its high mortality rate and its potential t

Pfizer beats profit estimates on heart disease drug, Covid vaccine sales

Pfizer is facing investor pressure to show that its recent acquisitions and investments can bring in returns